Increased Angiogenic Sprouting in Poor Prognosis FL is Associated with Elevated Numbers of CD163+ Macrophages Within the Immediate Sprouting Microenvironment

Overview

Journal Blood

Publisher Elsevier

Specialty Hematology

Date 2010 Apr 9

PMID 20375314

Citations 61

Authors

Andrew J Clear

Abigail M Lee

Maria Calaminici

Alan G Ramsay

Kelly J Morris

Simon Hallam

Gavin Kelly

Finlay MacDougall

T Andrew Lister

John G Gribben

Affiliations

Soon will be listed here.

Abstract

Follicular lymphoma has considerable clinical heterogeneity, and there is a need for easily quantifiable prognostic biomarkers. Microvessel density has been shown to be a useful prognostic factor based on numerical assessment of vessel numbers within histologic sections in some studies, but assessment of tumor neovascularization through angiogenic sprouting may be more relevant. We therefore examined the smallest vessels, single-staining structures measuring less than 30 microm(2) in area, seen within histologic sections, and confirmed that they were neovascular angiogenic sprouts using extended focal imaging. Tissue microarrays composing diagnostic biopsies from patients at the extremes of survival of follicular lymphoma were analyzed with respect to numbers of these sprouts. This analysis revealed higher angiogenic activity in the poor prognostic group and demonstrated an association between increased sprouting and elevated numbers of infiltrating CD163(+) macrophages within the immediate microenvironment surrounding the neovascular sprout.

Citing Articles

Molecular Biomarkers in Prediction of High-Grade Transformation and Outcome in Patients with Follicular Lymphoma: A Comprehensive Systemic Review.

Enemark M, Hemmingsen J, Jensen M, Kridel R, Ludvigsen M Int J Mol Sci. 2024; 25(20).

PMID: 39456961 PMC: 11508793. DOI: 10.3390/ijms252011179.

Bidirectional crosstalk between therapeutic cancer vaccines and the tumor microenvironment: Beyond tumor antigens.

Zhang S, Wang H, Ding X, Xiao Y, Shao Z, You C Fundam Res. 2024; 3(6):1005-1024.

PMID: 38933006 PMC: 11197801. DOI: 10.1016/j.fmre.2022.03.009.

Mesenchymal stem cells-macrophages crosstalk and myeloid malignancy.

Li K, Nie H, Jin R, Wu X Front Immunol. 2024; 15:1397005.

PMID: 38779660 PMC: 11109455. DOI: 10.3389/fimmu.2024.1397005.

Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer.

Han R, Guo H, Shi J, Zhao S, Jia Y, Liu X BMC Med. 2024; 22(1):174.

PMID: 38658988 PMC: 11040894. DOI: 10.1186/s12916-024-03389-w.

MRC1 and LYVE1 expressing macrophages in vascular beds of GNAQ p.R183Q driven capillary malformations in Sturge Weber syndrome.

Nasim S, Bichsel C, Dayneka S, Mannix R, Holm A, Vivero M Acta Neuropathol Commun. 2024; 12(1):47.

PMID: 38532508 PMC: 10964691. DOI: 10.1186/s40478-024-01757-4.

References

Canioni D, Salles G, Mounier N, Brousse N, Keuppens M, Morchhauser F . High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial. J Clin Oncol. 2007; 26(3):440-6. DOI: 10.1200/JCO.2007.12.8298. View

Sica A, Schioppa T, Mantovani A, Allavena P . Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur J Cancer. 2006; 42(6):717-27. DOI: 10.1016/j.ejca.2006.01.003. View

Federico M, Bellei M, Marcheselli L, Luminari S, Lopez-Guillermo A, Vitolo U . Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol. 2009; 27(27):4555-62. DOI: 10.1200/JCO.2008.21.3991. View

Montoto S, Davies A, Matthews J, Calaminici M, Norton A, Amess J . Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma. J Clin Oncol. 2007; 25(17):2426-33. DOI: 10.1200/JCO.2006.09.3260. View

Rao S, Lobov I, Vallance J, Tsujikawa K, Shiojima I, Akunuru S . Obligatory participation of macrophages in an angiopoietin 2-mediated cell death switch. Development. 2007; 134(24):4449-58. PMC: 3675770. DOI: 10.1242/dev.012187. View

Leek R, Lewis C, Whitehouse R, Greenall M, Clarke J, Harris A . Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res. 1996; 56(20):4625-9. View

Koster A, van Krieken J, MacKenzie M, Schraders M, Borm G, van der Laak J . Increased vascularization predicts favorable outcome in follicular lymphoma. Clin Cancer Res. 2005; 11(1):154-61. View

Klapper W, Hoster E, Rolver L, Schrader C, Janssen D, Tiemann M . Tumor sclerosis but not cell proliferation or malignancy grade is a prognostic marker in advanced-stage follicular lymphoma: the German Low Grade Lymphoma Study Group. J Clin Oncol. 2007; 25(22):3330-6. DOI: 10.1200/JCO.2006.10.5833. View

Podgrabinska S, Braun P, Velasco P, Kloos B, Pepper M, Skobe M . Molecular characterization of lymphatic endothelial cells. Proc Natl Acad Sci U S A. 2002; 99(25):16069-74. PMC: 138566. DOI: 10.1073/pnas.242401399. View

10.

de Jong D . Molecular pathogenesis of follicular lymphoma: a cross talk of genetic and immunologic factors. J Clin Oncol. 2005; 23(26):6358-63. DOI: 10.1200/JCO.2005.26.856. View

11.

Farinha P, Masoudi H, Skinnider B, Shumansky K, Spinelli J, Gill K . Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood. 2005; 106(6):2169-74. DOI: 10.1182/blood-2005-04-1565. View

12.

Cullen M, Lister T, Brearley R, Shand W, Stansfeld A . Histological transformation of non-Hodgkin's lymphoma: a prospective study. Cancer. 1979; 44(2):645-51. DOI: 10.1002/1097-0142(197908)44:2<645::aid-cncr2820440234>3.0.co;2-y. View

13.

Vacca A, Ribatti D, Ruco L, Giacchetta F, Nico B, Quondamatteo F . Angiogenesis extent and macrophage density increase simultaneously with pathological progression in B-cell non-Hodgkin's lymphomas. Br J Cancer. 1999; 79(5-6):965-70. PMC: 2362651. DOI: 10.1038/sj.bjc.6690154. View

14.

Ojalvo L, Whittaker C, Condeelis J, Pollard J . Gene expression analysis of macrophages that facilitate tumor invasion supports a role for Wnt-signaling in mediating their activity in primary mammary tumors. J Immunol. 2009; 184(2):702-12. PMC: 3226722. DOI: 10.4049/jimmunol.0902360. View

15.

Mason D, Micklem K, Jones M . Double immunofluorescence labelling of routinely processed paraffin sections. J Pathol. 2000; 191(4):452-61. DOI: 10.1002/1096-9896(2000)9999:9999<::AID-PATH665>3.0.CO;2-O. View

16.

Tjiu J, Chen J, Shun C, Lin S, Liao Y, Chu C . Tumor-associated macrophage-induced invasion and angiogenesis of human basal cell carcinoma cells by cyclooxygenase-2 induction. J Invest Dermatol. 2008; 129(4):1016-25. DOI: 10.1038/jid.2008.310. View

17.

Dave S, Wright G, Tan B, Rosenwald A, Gascoyne R, Chan W . Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med. 2004; 351(21):2159-69. DOI: 10.1056/NEJMoa041869. View

18.

Toge H, Inagaki T, Kojimoto Y, Shinka T, Hara I . Angiogenesis in renal cell carcinoma: the role of tumor-associated macrophages. Int J Urol. 2009; 16(10):801-7. DOI: 10.1111/j.1442-2042.2009.02377.x. View

19.

Johnson P, Rohatiner A, Whelan J, Price C, Love S, Lim J . Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center. J Clin Oncol. 1995; 13(1):140-7. DOI: 10.1200/JCO.1995.13.1.140. View

20.

Solal-Celigny P, Roy P, Colombat P, White J, Armitage J, Arranz-Saez R . Follicular lymphoma international prognostic index. Blood. 2004; 104(5):1258-65. DOI: 10.1182/blood-2003-12-4434. View